HEPION PHARMACEUTICALS, INC.: 10-Q filed 2023-11-20

Name: HEPION PHARMACEUTICALS, INC.: 10-Q filed 2023-11-20
Creator: HEPION PHARMACEUTICALS, INC.

What HEPION PHARMACEUTICALS, INC. reported in its quarterly report filed 2023-11-20 (fiscal Q3 2023): 39 published measures, 119 facts as tagged in accession 0001583771-23-000013.

This filing

Form: 10-Q (quarterly report)
Filed: 2023-11-20
Fiscal period: fiscal Q3 2023
Accession: 0001583771-23-000013 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All HEPION PHARMACEUTICALS, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

Period	Value	Unit	Days
At 2023-09-30	25,003,108	USD
At 2022-12-31	60,244,452	USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

Period	Value	Unit	Days
At 2023-09-30	8,844,351	USD
At 2022-12-31	10,388,515	USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

Period	Value	Unit
At 2023-09-30	16,158,757	USD
At 2023-06-30	26,373,069	USD
At 2023-03-31	37,152,492	USD
At 2022-12-31	49,855,937	USD
At 2022-09-30	59,258,942	USD
At 2022-06-30	67,320,321	USD
At 2022-03-31	86,636,082	USD
At 2021-12-31	92,995,003	USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

Period	Value	Unit	Days
2023-07-01 to 2023-09-30	-10,526,946	USD	92
2023-01-01 to 2023-09-30	-37,866,414	USD	273
2023-04-01 to 2023-06-30	-14,079,547	USD	91
2023-01-01 to 2023-03-31	-13,259,921	USD	90
2022-07-01 to 2022-09-30	-8,547,591	USD	92
2022-01-01 to 2022-09-30	-35,388,575	USD	273
2022-04-01 to 2022-06-30	-19,911,299	USD	91
2022-01-01 to 2022-03-31	-6,929,685	USD	90

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

Period	Value	Unit	Days
2023-01-01 to 2023-09-30	-31,887,104	USD	273
2022-01-01 to 2022-09-30	-30,163,670	USD	273

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

Period	Value	Unit	Days
2023-01-01 to 2023-09-30	13,956	USD	273
2022-01-01 to 2022-09-30	0	USD	273

Contract revenue excluding tax

Revenue from customer contracts excluding assessed taxes under this specific taxonomy concept. It is not automatically comparable to older revenue tags.

Period	Unit	Days
2023-07-01 to 2023-09-30	USD	92
2023-01-01 to 2023-09-30	USD	273
2022-07-01 to 2022-09-30	USD	92
2022-01-01 to 2022-09-30	USD	273

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

Period	Value	Unit	Days
2023-01-01 to 2023-09-30	0	USD	273
2022-01-01 to 2022-09-30	-2,000,000	USD	273

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

Period	Value	Unit	Days
2023-01-01 to 2023-09-30	-13,956	USD	273
2022-01-01 to 2022-09-30	2,266	USD	273

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

Period	Value	Unit	Days
At 2023-09-30	-213,567,758	USD
At 2022-12-31	-175,701,344	USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

Period	Value	Unit	Days
2023-07-01 to 2023-09-30	3,838,289	shares	92
2023-01-01 to 2023-09-30	3,825,523	shares	273
2022-07-01 to 2022-09-30	3,811,481	shares	92
2022-01-01 to 2022-09-30	3,811,469	shares	273

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

Period	Value	Unit	Days
2023-07-01 to 2023-09-30	3,838,289	shares	92
2023-01-01 to 2023-09-30	3,825,523	shares	273
2022-07-01 to 2022-09-30	3,811,481	shares	92
2022-01-01 to 2022-09-30	3,811,469	shares	273

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

Period	Value	Unit	Days
2023-07-01 to 2023-09-30	-2.74	USD/shares	92
2023-01-01 to 2023-09-30	-9.9	USD/shares	273
2022-07-01 to 2022-09-30	-2.24	USD/shares	92
2022-01-01 to 2022-09-30	-9.28	USD/shares	273

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

Period	Value	Unit	Days
2023-07-01 to 2023-09-30	-2.74	USD/shares	92
2023-01-01 to 2023-09-30	-9.9	USD/shares	273
2022-07-01 to 2022-09-30	-2.24	USD/shares	92
2022-01-01 to 2022-09-30	-9.28	USD/shares	273

Income tax expense or benefit

Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.

Period	Unit	Days
2023-07-01 to 2023-09-30	USD	92
2023-01-01 to 2023-09-30	USD	273
2022-07-01 to 2022-09-30	USD	92
2022-01-01 to 2022-09-30	USD	273

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

Period	Value	Unit	Days
At 2023-09-30	41,087	USD
At 2022-12-31	81,620	USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

Period	Value	Unit	Days
2023-01-01 to 2023-09-30	1,189,988	USD	273
2022-01-01 to 2022-09-30	2,320,793	USD	273

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

Period	Value	Unit	Days
2023-07-01 to 2023-09-30	-10,664,565	USD	92
2023-01-01 to 2023-09-30	-38,039,360	USD	273
2022-07-01 to 2022-09-30	-8,465,326	USD	92
2022-01-01 to 2022-09-30	-35,715,915	USD	273

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

Period	Value	Unit	Days
At 2023-09-30	21,269,436	USD
At 2022-12-31	56,496,073	USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

Period	Value	Unit	Days
2023-07-01 to 2023-09-30	2,381	USD	92
2023-01-01 to 2023-09-30	7,054	USD	273
2022-07-01 to 2022-09-30	2,265	USD	92
2022-01-01 to 2022-09-30	7,652	USD	273

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

Period	Value	Unit	Days
At 2023-09-30	6,402,498	USD
At 2022-12-31	7,885,722	USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

Period	Value	Unit	Days
At 2023-09-30	3,006,221	USD
At 2022-12-31	2,665,896	USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

Period	Value	Unit	Days
2023-07-01 to 2023-09-30	10,664,565	USD	92
2023-01-01 to 2023-09-30	38,039,360	USD	273
2022-07-01 to 2022-09-30	8,465,326	USD	92
2022-01-01 to 2022-09-30	35,715,915	USD	273

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

Period	Value	Unit	Days
2023-07-01 to 2023-09-30	8,518,520	USD	92
2023-01-01 to 2023-09-30	30,196,848	USD	273
2022-07-01 to 2022-09-30	5,740,122	USD	92
2022-01-01 to 2022-09-30	25,753,211	USD	273

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

Period	Value	Unit	Days
At 2023-09-30	3,838,289	shares
At 2022-12-31	3,811,481	shares

Cash including restricted cash

Cash, cash equivalents and restricted cash as reported in the cash flow reconciliation. Restricted amounts are not freely available, so this is not the same as unrestricted cash.

Period	Value	Unit
At 2023-09-30	19,284,080	USD
At 2022-12-31	51,189,088	USD
At 2022-09-30	59,145,193	USD
At 2021-12-31	91,348,967	USD

Accumulated other comprehensive income or loss

Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.

Period	Value	Unit	Days
At 2023-09-30	-93,928	USD
At 2022-12-31	-90,168	USD

Operating lease right-of-use asset

Carrying amount of the right to use leased assets under operating leases. It reflects discounted remaining payments, not the value of the underlying property.

Period	Value	Unit	Days
At 2023-09-30	242,507	USD
At 2022-12-31	50,585	USD

Operating lease liability

Present value of remaining operating lease payments. Discount-rate choices and lease terms affect the amount; it is not the sum of undiscounted future rent.

Period	Value	Unit	Days
At 2023-09-30	241,543	USD

Accumulated depreciation on property, plant and equipment

Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.

Period	Value	Unit	Days
At 2023-09-30	361,229	USD
At 2022-12-31	306,945	USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

Period	Value	Unit	Days
At 2023-09-30	2,907,565	USD
At 2022-12-31	4,799,983	USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

Period	Value	Unit	Days
At 2023-09-30	1,985,356	USD
At 2022-12-31	5,306,985	USD

Net deferred tax liabilities

Deferred tax liabilities net of related assets under this concept. The amount reflects timing differences and is not tax currently due.

Period	Value	Unit	Days
At 2023-09-30	409,022	USD
At 2022-12-31	409,022	USD

Pre-tax income or loss from continuing operations

Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.

Period	Value	Unit	Days
2023-07-01 to 2023-09-30	-10,526,946	USD	92
2023-01-01 to 2023-09-30	-37,866,414	USD	273
2022-07-01 to 2022-09-30	-8,547,591	USD	92
2022-01-01 to 2022-09-30	-35,388,575	USD	273

Comprehensive income or loss

Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.

Period	Value	Unit	Days
2023-07-01 to 2023-09-30	-10,533,223	USD	92
2023-01-01 to 2023-09-30	-37,870,174	USD	273
2022-07-01 to 2022-09-30	-8,607,959	USD	92
2022-01-01 to 2022-09-30	-35,478,910	USD	273

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

Period	Value	Unit	Days
2023-07-01 to 2023-09-30	2,146,045	USD	92
2023-01-01 to 2023-09-30	7,842,512	USD	273
2022-07-01 to 2022-09-30	2,725,204	USD	92
2022-01-01 to 2022-09-30	8,091,780	USD	273

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

Period	Value	Unit	Days
2023-07-01 to 2023-09-30	18,500	USD	92
2023-01-01 to 2023-09-30	54,866	USD	273
2022-07-01 to 2022-09-30	17,726	USD	92
2022-01-01 to 2022-09-30	58,985	USD	273

Depreciation, depletion and amortization

Combined depreciation, depletion and amortization for the period. A noncash allocation of asset cost, not a measure of maintenance spending.

Period	Value	Unit	Days
2023-01-01 to 2023-09-30	54,866	USD	273
2022-01-01 to 2022-09-30	58,985	USD	273

Interest paid, net

Cash interest paid during the period, net of amounts capitalized where the filer reports it that way. It differs from interest expense recognized.

Period	Value	Unit	Days
2023-01-01 to 2023-09-30	0	USD	273
2022-01-01 to 2022-09-30	941	USD	273

Inspect the source

Entity: HEPION PHARMACEUTICALS, INC. / CIK 0001583771
Captured: 2026-09-20T09:23:01.444Z
SEC response SHA-256: 8713b65a28b6abe1fe9df431214197b2d073688f1082552d43175ea3504e60ff

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001583771.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))